Patents by Inventor Jeffrey D. Kent

Jeffrey D. Kent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REDUCING IMMUNOGENICITY TO PEGLOTICASE
    Publication number: 20240033331
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and MMF. Also provided are methods of reducing intolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MMF.
    Type: Application
    Filed: October 4, 2023
    Publication date: February 1, 2024
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX
  • REDUCING IMMUNOGENICITY TO PEGLOTICASE
    Publication number: 20230173035
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.
    Type: Application
    Filed: September 28, 2022
    Publication date: June 8, 2023
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX, John BOTSON, Jeff PETERSON
  • COMBINATION THERAPIES OF PREDNISONE AND URICASE MOLECULES AND USES THEREOF
    Publication number: 20230085022
    Abstract: Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and/or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 16, 2023
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX
  • REDUCING IMMUNOGENICITY TO PEGLOTICASE
    Publication number: 20220409620
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 29, 2022
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX, John BOTSON, Jeff PETERSON
  • REDUCING IMMUNOGENICITY TO PEGLOTICASE
    Publication number: 20200237880
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and MMF. Also provided are methods of reducing intolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MMF.
    Type: Application
    Filed: January 30, 2020
    Publication date: July 30, 2020
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX
  • REDUCING IMMUNOGENICITY TO PEGLOTICASE
    Publication number: 20200237881
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.
    Type: Application
    Filed: January 30, 2020
    Publication date: July 30, 2020
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX, John BOTSON, Jeff PETERSON
  • TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE)
    Publication number: 20200237879
    Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.
    Type: Application
    Filed: January 30, 2020
    Publication date: July 30, 2020
    Inventors: Jeffrey D. KENT, Brian LAMOREAUX
  • USES AND COMPOSITIONS FOR TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20170157249
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: July 21, 2016
    Publication date: June 8, 2017
    Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez
  • Methods for determining efficacy of TNF-? inhibitors for treatment of rheumatoid arthritis
    Patent number: 9399061
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: July 26, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez, Gerd R. Burmester, Philip Mease, Daniel J. Lovell, Edward Keystone, Arthur Kavanaugh
  • Uses and Compositions for Treatment of Rheumatoid Arthritis
    Publication number: 20150064194
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: October 28, 2014
    Publication date: March 5, 2015
    Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez
  • USES AND COMPOSITIONS FOR TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20150064195
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: October 28, 2014
    Publication date: March 5, 2015
    Inventors: HARTMUT KUPPER, JEFFREY D. KENT, MARY A. CIFALDI, JOHN L. PEREZ
  • Uses and Compositions for Treatment of Rheumatoid Arthritis
    Publication number: 20150056212
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 26, 2015
    Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez
  • USES AND COMPOSITIONS FOR TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20120171123
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: October 25, 2011
    Publication date: July 5, 2012
    Inventors: John R. Medich, Hartmut Kupper, John L. Perez, Jeffrey D. Kent, Eric H. Sasso, Oscar Segurado, George Spencer-Green, Theodore Pincus
  • Uses and compositions for treatment of rheumatoid arthritis
    Publication number: 20080166348
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: April 10, 2007
    Publication date: July 10, 2008
    Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez, Gerd R. Burmester, Philip Mease, Daniel J. Lovell, Edward Keystone, Arthur Kavanaugh
  • Uses and compositions for treatment of rheumatoid arthritis
    Publication number: 20080131374
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: May 4, 2007
    Publication date: June 5, 2008
    Inventors: John R. Medich, Hartmut Kupper, Jeffrey D. Kent, John L. Perez, Eric H. Sasso, Oscar Segurado, George Spencer-Green, Theodore Pincus